Results: Pts reaching clinical remission had significant lower baseline BME sum scores then the non-remission group (mean 1.86 vs. 2.89, p=0.024). At the time of clinical remission 10/45 (22%) and 11/45 (24%) pts had residual talocarpal and subtalar synovitis respectively. However, there was no statistically significant difference between patients who relapsed after treatment withdrawal and those who remained in remission concerning synovitis sum scores (p=0.497) as well as BME sum scores (p=0.741) and STI sum scores (p=0.131) at time of clinical remission (table 1).

Abstract FR0177 – Table 1. BME, synovitis and STI presence in early pSpA pts who relapsed and did not relapse after stopping golimumab therapy

<table>
<thead>
<tr>
<th>Patients relapsed (n=20)</th>
<th>Patients not relapsed (n=25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BME at baseline</td>
<td>1.82 (±1.29)</td>
</tr>
<tr>
<td>BME at follow-up</td>
<td>1.32 (±1.12)</td>
</tr>
<tr>
<td>Change score BME</td>
<td>0.50 (±1.36)</td>
</tr>
<tr>
<td>Synovitis at baseline</td>
<td>2.53 (±3.11)</td>
</tr>
<tr>
<td>Synovitis at follow-up</td>
<td>1.13 (±1.41)</td>
</tr>
<tr>
<td>Change score synovitis</td>
<td>1.50 (±2.71)</td>
</tr>
<tr>
<td>STI at baseline</td>
<td>1.67 (±1.81)</td>
</tr>
<tr>
<td>STI at follow-up</td>
<td>0.93 (±0.75)</td>
</tr>
<tr>
<td>Change score STI</td>
<td>0.70 (±1.34)</td>
</tr>
</tbody>
</table>

Conclusions: Early pSpA pts who reach clinical remission have less BME on baseline WB MRI compared to those with ongoing disease activity. At time of clinical remission, a substantial number of the participants showed persistent synovitis on MRI. However, residual inflammatory lesions detected by WB MRI did not differ significantly between pts who relapsed after treatment withdrawal and those in ongoing clinical remission.

Disclosure of Interest: None declared


FR0179 INTEGRATED LONGITUDINAL ANALYSIS INCREASES PRECISION AND REDUCES BIAS: A COMPARATIVE 5-YEAR ANALYSIS IN THE DESIR COHORT

A. Sepulveda1, S. Ramirez2, D. van der Heijide1, M. Dougados3, P. Claudepiere4, A. Feydy5, M. Reijnierse6, D. Louelle7, R. Landewé7,8,9,10,11, Rheumatology, Leiden University Medical Centre, Leiden, Netherlands; 2Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris; 3Radiology, Hôpital Henri-Mondor, Creteil; 4Radiology, Hôpital Cochin, Hôpitaux de Paris, Paris, France; 5Radiology, Leiden University Medical Centre, Leiden, Netherlands; 6Rheumatology, Hospital Barroso, Nancy, France; 7Rheumatology, Amsterdam Rheumatology and Clinical Immunology Center (ARC), Amsterdam, Netherlands

Background: Evaluation of imaging is important in spondyloarthritis (SpA) research, but loss to follow up often jeopardises interpretation of the evaluation. The Interpretation may further be challenged by the fact that often different readers have contributed to scores, in multiple reading-waves. A common approach is to evaluate patients (pts) with complete follow up (completers analysis), and aggregate scores of individual readers (eg. agreement ≥2 of 3 readers). These approaches are not assumption-free, may cause non-random data loss, and may as such provide spurious estimates and loss of external validity.

Objectives: We aimed to investigate if the use of all data in an assumption-free manner (a so called ‘integrated analysis’) affects the precision of estimates for imaging outcomes in pts with axial SpA (axSpA), with completers analysis as reference standard.

Methods: Pts from the DESIR cohort fulfilling the ASAS axSpA criteria were included. Radiographs and MRIs of the SJ and spine were obtained at baseline (BL), 1, 2 and 5 years. Each film was scored by 2 or 3 readers in 3 ‘reading-waves’ (wave 1: BL only; wave 2: BL, 1, 2 years; wave 3: BL, 2, 5 years). Each outcome was analysed in two ways: i. according to a ‘combination algorithm’ (2 out of 3 for binary and mean of 3 for continuous variables); and ii. per individual reader. The change of each outcome was analysed by generalised estimating equations (GEE) with ‘time’ as explanatory variable. Three analytical approaches were pursued: i. ‘integrated-analysis’ (including all pts with ≥1 score from ≥1 reader from all waves); ii. completers-only analysis (including only pts with complete 5 year follow-up, using scores from individual readers from wave 3); iii) aggregated completers analysis using a combination algorithm (the same as ii but using combined scores).

Results: In total, 413 pts were included (mean SD symptom duration: 1.6 (0.9) years) and 366 completed the 5 year follow up. An analysis with all data from different readers and ‘waves’ (‘integrated analysis’) was more inclusive, but did not result in a meaningful loss of precision (width of 95%CIs) of the change-estimates as compared to both completers analyses (table 1). In fact, for low-incidence outcomes (e.g. % of mNY-positive over 5 years), a similar incidence was captured, with more precision, by the ‘integrated analysis’ compared to the

Conclusions: An efficient and entirely assumption-free usage of all data from different readers and ‘read-waves’ does not compromise precision of the estimates of change in imaging parameters, and may yield increased statistical power for detecting changes with low incidence. In addition, integrated analysis may protect against attrition bias and avoid bias by ‘convenient choices’.

Disclosure of Interest: None declared


FRI0180 DIAGNOSIS JOURNEY OF PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE UNITED STATES

A. Ogdie1, W.B. Nowell2, R. Reynolds3, K. Gavigian4, S. Venkatachalam5, M. de la Cruz6, E.J. Flood2, E.J. Schwartz7, B. Romero8, Y. Park4, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia; 2Global Healthy Living Foundation, Upper Nyack; 3ICON, Gathersburg; 4Novartis Pharmaceuticals Corporation, East Hanover, USA

Background: A US-based study demonstrated that patients with ankylosing spondylitis (AS) experience a significant delay (on average 14 years) from symptom onset to diagnosis of AS. Understanding the diagnosis journey of patients with AS and identifying opportunities to reduce misdiagnosis and incorrect referral are crucial to reducing time to diagnosis, preventing irreversible joint damage, and preserving mobility.

Objectives: To describe the patient journey to AS diagnosis from the patient perspective and differences observed between females and males.

Methods: US adults aged ≥18 years with a self-reported diagnosis of AS were recruited through CreativeJoints, an online patient support community comprising patients with arthritis and arthritis-related diseases and their caregivers. Respondents completed a web-based survey on socio-demographics, clinical symptoms, disease burden, and diagnosis history, which included symptoms that led to seeking care, time from symptom onset to seeking care and from seeking care to AS diagnosis, types of healthcare providers seen, and misdiagnoses. Survey questions were developed following qualitative interviews of patients with AS and clinical experts, as well as a targeted literature review. Survey results were compared between females and males using 2-sample t-tests for continuous variables and chi squared tests for categorical variables.

Results: Among 225 respondents, 174 (74%) were female. Mean (SD) age of female and male respondents were 48.6 (10.6) and 53.1 (10.3) years, respectively. Although the majority (58% female and 54% male) sought medical care within the first year of symptom onset, female respondents reported a mean of 17.2 years since first symptom onset and 7.5 years since AS diagnosis; while male respondents reported a mean of 20.0 years since first symptom onset and 11.4 years since AS diagnosis. The most common symptoms that led to seeking medical care were back pain, joint pain, stiffness, and fatigue (figure 1A). During the diagnosis process, patients reported seeking medical care from a general practitioner (87%), rheumatologist (65%), orthopedist (27%), chiropractor (28%), and urgent care/emergency room doctor (21%) with no differences between females and males. The most commonly reported misdiagnoses were back problems (56%), psychosomatic (23%), and sciatica (21%) in males, while psychosomatic (41%), back problems (40%), and anxiety/depression (24%) were most common in females. Significantly higher proportions of females reported misdiagnoses of fibromyalgia (21% vs 7%) and psychosomatic (41% vs 23%) (figure 1B).
Abstract FRI0180 – Figure 1. Most common first symptom to prompt seeking care (A) and most common misdiagnoses (B) in patients with AS

Conclusions: The diagnostic process differs among males and females with AS. Our study findings highlight gender differences in initial symptom presentation, misdiagnoses, and time to diagnosis of AS.

REFERENCE:

Acknowledgements: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ.

Disclosure of Interest: A. Ogdie Grant/research support from: Pfizer and Novartis, Consultant for: Abbvie, BMS, Eli Lilly and Company, Novartis, Takeda, and Pfizer.

Background: Anti-tumour necrosis factor (anti-TNF) agents can induce progression from latent tuberculosis infection (LTBI) to active tuberculosis (TB) in patients with rheumatic diseases[1][2]. In a high tuberculosis incidence setting, TB cases developed despite the screening and treatment for LTBI.

Objectives: To identify, in a high TB incidence setting, the TB incidence rate in patients with spondyloarthritis (SpA) during twelve years of follow-up.

Methods: Electronic medical records from patients attending the SpA Clinic between 2004 and 2016 in a public university hospital were reviewed. Patients were grouped in those exposed to anti-TNF therapy and those non-exposed. The tuberculin skin test incidence rate (IR) was calculated for both groups and expressed as number of events per 1 000 patients/year; the incidence rate ratio (IRR) associated to the anti-TNF therapy was calculated.

Results: A total of 274 patients were evaluated, 102 exposed to anti-TNF drugs and 172 non-exposed. All the 102 patients undergoing screening for LTBI before anti-TNF therapy: 38.2% (n=39) were diagnosed with LTBI and underwent 6 months of isoniazid preventive therapy (IPT). The total follow-up time (in patients/year) was 729 in the group exposed to anti-TNF and 1243 in the group non-exposed. Ten patients were diagnosed with TB: 4 exposed to anti-TNF therapy and 6 non-exposed. Among the 4 patients exposed to anti-TNF therapy who developed TB, three had negative screening for LTBI. The TB IR (per 1 000 patients/year) was 548, compared to 321 in non-exposed; the IRR associated with the use of anti-TNF drugs was 1.7.

Conclusions: In a region with high TB prevalence, patients with SpA exposed to anti-TNF drugs had a higher incidence of TB compared to those who have never been exposed to these drugs. Our data reinforces the American College of Rheumatology’s recommendation that patients who live in endemic TB settings should be tested annually for LTBI.

REFERENCES:

Disclosure of Interest: None declared


<table>
<thead>
<tr>
<th>MRI Spine</th>
<th>CBP n=98</th>
<th>SpA n=100</th>
<th>OR 95% CI SE Spe LR+</th>
</tr>
</thead>
<tbody>
<tr>
<td>N(%) patients with at least one structural lesion</td>
<td>16/95 (16.8%)</td>
<td>24 (24%)</td>
<td>0.2 (0.2–0.3) 0.8 (0.7–0.9) 1.4 (0.8–2.5)</td>
</tr>
<tr>
<td>N(%) patients with ≥3 subchondral bone erosions</td>
<td>10/95 (10.5%)</td>
<td>&lt;0.001 (0.2–0.4) 0.9 (0.8–1.0) 3.0 (1.6–5.8)</td>
<td></td>
</tr>
<tr>
<td>N(%) patients with ≥3 subchondral bone fatty lesions</td>
<td>29 (29%)</td>
<td>0.29 (0.2–0.4) 0.88 (0.8–1.0) 2.5 (1.3–4.7)</td>
<td></td>
</tr>
<tr>
<td>N(%) patients with ≥5 subchondral bone erosions or fatty lesions</td>
<td>13/95 (13.7%)</td>
<td>0.002 (0.2–0.4) 0.9 (0.8–1.0) 2.4 (1.4–4.3)</td>
<td></td>
</tr>
</tbody>
</table>

FRIO181
TWO YEARS FOLLOW-UP OF PATIENTS WITH SPONDYLOARTHRITIS IN AN ENDEMIC CITY DEMONSTRATES HIGH RISK OF ACTIVE TUBERCULOSIS INFECTION

A. Morsch1, D. Silva1,2, G. Garziera1,2, M. Ferreira1, C. Koheni1,2, R. Xavier1,2, A. Gaspari1, C. Brenol1, R. Bohrn1, N. de Andrade1, D. Viecell1, F. Menegat1, P. Palominos1,1 Hospital de Clinicas de Porto Alegre; 2Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

Background: Anti-tumour necrosis factor (anti-TNF) agents can induce progression from latent tuberculosis infection (LTBI) to active tuberculosis (TB) in patient with rheumatic diseases[1][2]. In a high tuberculosis incidence setting, TB cases developed despite the screening and treatment for LTBI.

Objectives: To identify, in a high TB incidence setting, the TB incidence rate in patients with spondyloarthritis (SpA) during twelve years of follow-up.

Methods: Electronic medical records from patients attending the SpA Clinic between 2004 and 2016 in a public university hospital were reviewed. Patients were grouped in those exposed to anti-TNF therapy and those non-exposed. The tuberculin skin test incidence rate (IR) was calculated for both groups and expressed as number of events per 1 000 patients/year; the incidence rate ratio (IRR) associated to the anti-TNF therapy was calculated.

Results: A total of 274 patients were evaluated, 102 exposed to anti-TNF drugs and 172 non-exposed. All the 102 patients undergoing screening for LTBI before anti-TNF therapy: 38.2% (n=39) were diagnosed with LTBI and underwent 6 months of isoniazid preventive therapy (IPT). The total follow-up time (in patients/year) was 729 in the group exposed to anti-TNF and 1243 in the group non-exposed. Ten patients were diagnosed with TB: 4 exposed to anti-TNF therapy and 6 non-exposed. Among the 4 patients exposed to anti-TNF therapy who developed TB, three had negative screening for LTBI. The TB IR (per 1 000 patients/year) was 548, compared to 321 in non-exposed; the IRR associated with the use of anti-TNF drugs was 1.7.

Conclusions: In a region with high TB prevalence, patients with SpA exposed to anti-TNF drugs had a higher incidence of TB compared to those who have never been exposed to these drugs. Our data reinforces the American College of Rheumatology’s recommendation that patients who live in endemic TB settings should be tested annually for LTBI.

Acknowledgements: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ.

Disclosure of Interest: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5640